NO138675B - DIAGNOSTIC PROCEDURE FOR DETECTION OF HUMAN CHORIONIC GONADOTROPINE, HUMAN ALBUMIN OR A RHEUMATOID FACTOR - Google Patents
DIAGNOSTIC PROCEDURE FOR DETECTION OF HUMAN CHORIONIC GONADOTROPINE, HUMAN ALBUMIN OR A RHEUMATOID FACTOR Download PDFInfo
- Publication number
- NO138675B NO138675B NO1749/72A NO174972A NO138675B NO 138675 B NO138675 B NO 138675B NO 1749/72 A NO1749/72 A NO 1749/72A NO 174972 A NO174972 A NO 174972A NO 138675 B NO138675 B NO 138675B
- Authority
- NO
- Norway
- Prior art keywords
- human
- albumin
- reagent
- polymer
- detection
- Prior art date
Links
- 102000008100 Human Serum Albumin Human genes 0.000 title claims description 13
- 108091006905 Human Serum Albumin Proteins 0.000 title claims description 13
- 238000001514 detection method Methods 0.000 title claims description 7
- 238000002405 diagnostic procedure Methods 0.000 title description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 14
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 13
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 13
- 239000004816 latex Substances 0.000 claims description 13
- 229920000126 latex Polymers 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 11
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 10
- 108010074605 gamma-Globulins Proteins 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 8
- 239000004793 Polystyrene Substances 0.000 claims description 7
- 239000007900 aqueous suspension Substances 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 229920002223 polystyrene Polymers 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 claims description 3
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 claims description 3
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000005484 gravity Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229920002717 polyvinylpyridine Polymers 0.000 claims description 3
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 3
- WRVRNZNDLRUXSW-UHFFFAOYSA-N acetic acid;prop-2-enoic acid Chemical compound CC(O)=O.OC(=O)C=C WRVRNZNDLRUXSW-UHFFFAOYSA-N 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 19
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 230000004520 agglutination Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 210000001006 meconium Anatomy 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940015047 chorionic gonadotropin Drugs 0.000 description 3
- 230000016615 flocculation Effects 0.000 description 3
- 238000005189 flocculation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000003630 glycyl group Chemical class [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Ifølge norsk patentarisøkning 241/72 fremstilles et vann-uløselig immunologisk-diagnostisk reagens til undersøkelse av nærvær av antistoffer eller antigener i kroppsvæsker, hvilket reagens har en spesifikk vekt tilnærmet vannets og består av en vandig suspensjon som inneholder adskilte partikler av en serologisk inert latex-polymer som gjennom en amidbinding er kondensert med humant choriongonadotropin, humant serum-albumin eller denaturert gamma-globulin. According to Norwegian patent extension 241/72, a water-insoluble immunological-diagnostic reagent is produced for the examination of the presence of antibodies or antigens in body fluids, which reagent has a specific weight approximately that of water and consists of an aqueous suspension containing separated particles of a serologically inert latex polymer which, through an amide bond, is condensed with human chorionic gonadotropin, human serum albumin or denatured gamma globulin.
Nærværende oppfinnelse vedrører en diagnostisk fremgangsmåte for påvisning av humant chorionisk gonadotropin, humant albumin eller en reumatoid faktor i kroppsvæsker fra mennesker. Denne diagnose av patologiske tilstander eller andre helsetilstander når det gjelder mennesker såvel som dyr fore-tas ofte ved anvendelse av immunologiske prinsipper. Disse prinsipper anvendes for å bestemme nærvær av antistoffer eller antigener i ^kroppsvæsken til det levende vesen. Et antigen er er fremmed stoff som, når det tilføres pasienten, bevirker produksjon av visse løselige stoffer som betegnes som antistoffer. Ethvert fremmed stoff, f.eks. protein, som ikke normalt er nærværende hos vedkommende vesen, kan forårsake dannelse av antistoffer når det tilføres individet under passende betingelser. The present invention relates to a diagnostic method for the detection of human chorionic gonadotropin, human albumin or a rheumatoid factor in body fluids from humans. This diagnosis of pathological conditions or other health conditions in the case of humans as well as animals is often carried out by applying immunological principles. These principles are used to determine the presence of antibodies or antigens in the body fluid of the living being. An antigen is a foreign substance which, when administered to the patient, causes the production of certain soluble substances known as antibodies. Any foreign substance, e.g. protein, which is not normally present in the organism concerned, can cause the formation of antibodies when administered to the individual under appropriate conditions.
Antikroppene reagerer etter at de er dannet med antigenet og vil således i tilfelle av mikrobielle eller virus-angrep beskytte mot infeksjoner. The antibodies react after they have been formed with the antigen and will thus protect against infections in the event of microbial or viral attacks.
Immunologiske testings-fremgangsmåter er basert på antigen-antistoff-reaksjonen, som vanligvis gir seg tilkjenne ved uløselighet eller agglutinering. Immunological testing procedures are based on the antigen-antibody reaction, which is usually manifested by insolubility or agglutination.
Vanligvis vil nærvær av et antigen eller et antistoff be-kreftes eller diagnoseres ved å bringe det tilsvarende antistoff eller antigen i kontakt med en kroppsvæske fra individet, vanligvis urin, blodserum eller spesielt behandlet blodek-strakt, selv om andre kroppsvæsker også kan anvendes. Nærvær av antistoff eller antigenet i individet kan fastslås hvis det dannes et uløselig antigen-antistoff-kompleks. Usually, the presence of an antigen or an antibody will be confirmed or diagnosed by bringing the corresponding antibody or antigen into contact with a body fluid from the individual, usually urine, blood serum or specially treated blood extract, although other body fluids can also be used. The presence of antibody or the antigen in the individual can be determined if an insoluble antigen-antibody complex is formed.
På grunn av at enkelte komplekser dannes meget sakte og.har meget liten partikkelstørrelse, så er det nødvendig å anvende bærestoffer for å muliggjøre en synlig påvisning. Blant anvendte bærestoffer er saue- og menneske-erythrocyter, bak-terieceller, bentonitt, latex-partikler, f.eks. polystyren, anioniske fenolharpikser og finfordelt diazotert aminocellu-lose. Due to the fact that certain complexes are formed very slowly and have a very small particle size, it is necessary to use carriers to enable visible detection. Among the carriers used are sheep and human erythrocytes, bacterial cells, bentonite, latex particles, e.g. polystyrene, anionic phenolic resins and finely divided diazotized aminocellulose.
Kjente bærestoffer som fysikalsk binder serologiske bestem-melsesmaterialer er begrenset med hensyn til anvendbarhet og nytte ved immunologisk diagnostiske fremgangsmåter da de lider av et antall ulemper. Bland viktige ulemper er ofte mangel på sensibilitet og i mange tilfeller dårlig stabilitet. Disse mangler skyldes primært det faktum at når latex-partiklene er fysikalsk overtrukket med det serologisk-reaktive materialet så eksisterer det en likevekt mellom det frie og det bundne materialet. Dette resulterer i konkurransedyktig inhibering mellom det frie og det latex-bundne antistoffet eller antigenet når det gjelder det tilsvarende antigen eller den tilsvarende antikropp. Dessuten kan mange negativt ladede proteiner ikke fysikalsk overtrekke inertelatex-partikler uten hydrolytisk eller enzymatisk nedbryting. Denne behandling kan resultere i tilpasningsforandringer av strukturen, og som kan være skadelig for den spesielle reaksjonen. Små peptider lar seg ikke bruke selv under disse betingelser for fysikalsk belegging med inerte polymerer, hvilket begrenser anvendbar-heten av denne fremgangsmåten når det gjelder mange immuno-logiskdiagnostiske tester. Known carriers that physically bind serological determination materials are limited in their applicability and usefulness in immunological diagnostic methods as they suffer from a number of disadvantages. Among important disadvantages is often a lack of sensitivity and, in many cases, poor stability. These shortcomings are primarily due to the fact that when the latex particles are physically coated with the serologically reactive material, there is an equilibrium between the free and the bound material. This results in competitive inhibition between the free and the latex-bound antibody or antigen in the case of the corresponding antigen or antibody. Moreover, many negatively charged proteins cannot physically coat inert latex particles without hydrolytic or enzymatic degradation. This treatment may result in adaptive changes of the structure, which may be detrimental to the particular reaction. Small peptides cannot be used even under these conditions for physical coating with inert polymers, which limits the applicability of this method when it comes to many immunological diagnostic tests.
Det er således et behov for et bærestoff som er serologisk inert, og som med et vidt spektrum av serologiske bestem-melsesmaterialer, vil danne en diagnostisk anvendbar reagens, hvilken er stabil, spesifikk, sensibel og som fremskaffer en lett iakttagbar visuell vurdering på minimum av tid. There is thus a need for a carrier which is serologically inert, and which, with a wide spectrum of serological determination materials, will form a diagnostically usable reagent, which is stable, specific, sensitive and which provides an easily observable visual assessment of a minimum of time.
I norsk patentansøkning nr. 241/72 er omtalt et vannuløselig, immunologisk, diagnostisk reagens med en spesifikk vekt som tilsvarer ca. vannets spesifikke vekt, og som består av adskilte partikler av en serologisk inert latex-polymer, som er sammenkondensert via en amid-binding med et kjent serologisk bestemmelsesmateriale. Den serologisk inerte latex-polymer har en partikkelstørrelse på 0,01 - 0,9 um og er en karboksylert styren-butadien-kopolymer, karboksylert polystyren, karboksylert polystyren med amino-grupper, akrylsyre-polymer, metakrylsyrepolymer, akrylonitril<p>olymer, akrylonitril-butadien-styren-kopolymer, polyvinylacetat-aktylat, polyvinylpyridin eller vinylklorid-akrylat-kopolymer. In Norwegian patent application no. 241/72, a water-insoluble, immunological, diagnostic reagent with a specific weight corresponding to approx. the specific gravity of water, and which consists of separate particles of a serologically inert latex polymer, which are condensed together via an amide bond with a known serological determination material. The serologically inert latex polymer has a particle size of 0.01 - 0.9 µm and is a carboxylated styrene-butadiene copolymer, carboxylated polystyrene, carboxylated polystyrene with amino groups, acrylic acid polymer, methacrylic acid polymer, acrylonitrile<p>olymer, acrylonitrile-butadiene-styrene copolymer, polyvinyl acetate-actylate, polyvinylpyridine or vinyl chloride-acrylate copolymer.
Foreliggende oppfinnelse omfatter en fremgangsmåte for å påvise nærværet av humant choriongonadotropin, humant albumin eller en reumatoid faktor i menneskelige kroppsvæsker hvori væskeprøven i tilfelle av påvisning av humant choriongonadotropin eller humant albumin etter forutgående blanding med det tilsvarende antiserum bringes i kontakt med en vandig suspensjon av et vannuløselig diagnostisk reagens, The present invention comprises a method for detecting the presence of human chorionic gonadotropin, human albumin or a rheumatoid factor in human body fluids, in which, in the case of detection of human chorionic gonadotropin or human albumin, the fluid sample after prior mixing with the corresponding antiserum is brought into contact with an aqueous suspension of a water-insoluble diagnostic reagent,
i tilfelle av.påvisningen av en reumatoid faktor bringes direkte i kontakt med en vandig suspensjon av et vannuløselig immunologisk diagnostisk reagens, hvilket reagens har en spesifikk vekt nær vannets og består av adskilte partikler av en serologisk inert latex polymer hvortil er kondensert gjennom en amidbinding humant choriongonadotropin, humant serum albumin eller denaturert gammaglobulin og resultatene observeres, karakterisert ved at man anvender et reagens hvor humant choriongonadotropin, humant serum albumin eller denaturert gammaglobulin er knyttet til en latex polymer som er en karboksylsert styrenbutadienkopolymer, karboksylert polystyren, karboksylert polystyren med amino-grupper, akrylsyre polymer, akrylonitrilpolymer, metakrylsyre polymer, akrylonitril butadienstyrenkopolymer, polyvinylacetat akrylat, polyvinylpyridin eller vinylklorid- in the case of the detection of a rheumatoid factor is brought directly into contact with an aqueous suspension of a water-insoluble immunological diagnostic reagent, which reagent has a specific gravity close to that of water and consists of separate particles of a serologically inert latex polymer to which is condensed through an amide bond human chorionic gonadotropin, human serum albumin or denatured gamma globulin and the results are observed, characterized by using a reagent where human chorionic gonadotropin, human serum albumin or denatured gamma globulin is linked to a latex polymer which is a carboxylated styrene butadiene copolymer, carboxylated polystyrene, carboxylated polystyrene with amino groups , acrylic acid polymer, acrylonitrile polymer, methacrylic acid polymer, acrylonitrile butadiene styrene copolymer, polyvinyl acetate acrylate, polyvinylpyridine or vinyl chloride-
akrylatkopolymer og som har en partikkelstørrelse på 0,01 - 0,9 um. Produktet kan anvendes i passende konsentra- acrylate copolymer and which has a particle size of 0.01 - 0.9 µm. The product can be used in suitable concentrations
sjon avhengig av den spesielle test, hvorved egnede konsentrasjoner er fra 1,0 til 2,5 vekt-3, hvorved 1,3 vekt-% er foretrukket. Således anvendes f.eks. produktet tion depending on the particular test, whereby suitable concentrations are from 1.0 to 2.5 wt-3, whereby 1.3 wt-% is preferred. Thus, e.g. the product
som er dannet når humanchorion-gonadotropin kobles til bærestoff partikkelen som et diagnostisk reagens for bestemmelse av om en kvinne er gravid. Dette kan f.eks. utføres ved å plassere en dråpe av prøveurinen på et rent glass, blande en dråpe av antihuman-chorion-gonadotropinserum, og deretter tilsette en dråpe av HGG-bærestoffproduktet i vandig suspensjon. Innen to minutter kan resultater av prøven iakttas med en nøyaktighet på 90 - 98%. which is formed when human chorionic gonadotropin binds to the carrier particle as a diagnostic reagent for determining whether a woman is pregnant. This can e.g. is performed by placing a drop of the sample urine on a clean glass, mixing a drop of antihuman chorionic gonadotropin serum, and then adding a drop of the HGG carrier product in aqueous suspension. Within two minutes, the results of the test can be observed with an accuracy of 90 - 98%.
Fordelene ved en slik prøve er dens enkelhet, hurtighet, spesifikitet, nøyaktighet og mangelen på uriktige positive resultater. Grunnen til dette er åt man ikke har forstyrrelse av andre proteiner forårsaket av ikke-spesifikke besjiktning. The advantages of such a test are its simplicity, speed, specificity, accuracy and the lack of false positive results. The reason for this is that there is no interference with other proteins caused by non-specific coating.
Et annet eksempel er at produktet som er dannet når gamma-globulin kobles til bærestoff-partikkelen anvendes som et diagnostisk reagens for å bestemme hvorvidt en pasient har rheumatoid arthritis. Dette kan utføres ved f.eks. å plassere det buffrede test-serum på et objektglass og blande med en dråpe av gamma-globulin-bære-reagens i en vandig suspensjon. Innen ett minutt kan resultatene Another example is that the product formed when gamma globulin is linked to the carrier particle is used as a diagnostic reagent to determine whether a patient has rheumatoid arthritis. This can be done by e.g. placing the buffered test serum on a slide and mixing with a drop of gamma globulin carrier reagent in an aqueous suspension. Within a minute the results can
iakttas og forsøksresultatene er ca. 80% nøyaktige. observed and the experimental results are approx. 80% accurate.
Følgende eksempler illustrerer oppfinnelsen. The following examples illustrate the invention.
EKSEMPEL 1 EXAMPLE 1
Testen på human-albumin i meconium hvori reaqensene som The test for human albumin in meconium in which the reagents as
er fremstilt ifølge eksempel 2 i norsk patentansøkning 241/72 anvendes, utføres på følgende måte: 2 ml antihuman-albumin-serum tilsettes et prøverør av glass, hvoretter 1 ml meconium-løsning (1:50 volum) i saltløsning tilsettes. Deretter blandes det hele og inkuberes ved 37°C is prepared according to example 2 in Norwegian patent application 241/72 is used, is carried out in the following way: 2 ml of anti-human albumin serum is added to a glass test tube, after which 1 ml of meconium solution (1:50 volume) in saline solution is added. The whole is then mixed and incubated at 37°C
i 10 minutter. To dråper av albumin-bære-suspensjonen tilsettes og blandes. Etter 1 time ved 37°C kan prøve-resultatene iakttas, agglutinering indikerer mindre enn 16 ug/ml albumin-forekomst i meconium, oq ikke-agglutinerinq indikerer albumin på 16 ug/ml eller mere. Dette humanalbumin-nivå i meconium er unormalt høyt, og videre prøver kan ut-føres for å bestemme nærvær av en unormal tilstand eller en sykdomstilstand, f.eks. cystic fibrosis. for 10 minutes. Two drops of the albumin-carrier suspension are added and mixed. After 1 hour at 37°C, the test results can be observed, agglutination indicates less than 16 ug/ml albumin presence in the meconium, and non-agglutinating indicates albumin of 16 ug/ml or more. This human albumin level in the meconium is abnormally high, and further tests may be performed to determine the presence of an abnormal condition or a disease state, e.g. cystic fibrosis.
EKSEMPEL 2 EXAMPLE 2
Gamma-globulin-bære-partiklene fremstilt ifølge eksempel 3 The gamma globulin carrier particles prepared according to example 3
i norsk patentansøkning 241/72 suspenderes r en 0,1 M glycin-saltløsningsbuffer ved pH 8,2, og anvendes i en diagnostisk immunologisk test på rheumatoid arthritis som følger: in Norwegian patent application 241/72 r is suspended in a 0.1 M glycine salt solution buffer at pH 8.2, and used in a diagnostic immunological test for rheumatoid arthritis as follows:
50 microliter av test-serum legges på et rent objektglass, 50 microliters of test serum is placed on a clean slide,
en dråpe av 0,1 M glycin-saltløsnings-buffer ved pH 8,2 tilsettes og blandes ved hjelp av en påstrykningsstikke av tre. 2 dråper av det fremstilte reagenset tilsettes, a drop of 0.1 M glycine-saline buffer at pH 8.2 is added and mixed using a wooden swab. 2 drops of the prepared reagent are added,
og deretter blandes reagensene igjen. Objektglasset vippes frem og tilbake forsiktig i 1 minutt. Prøveresultatene kan deretter iakttas. En agglutinering på objektglasset indikerer et serum som inneholder rheumatoid-faktor. Ikke-agglutinering viser at serumet er fritt for rheumatoid-faktor. and then the reagents are mixed again. The slide is gently tilted back and forth for 1 minute. The test results can then be observed. An agglutination on the slide indicates a serum containing rheumatoid factor. Non-agglutination shows that the serum is free of rheumatoid factor.
EKSEMPEL 3 EXAMPLE 3
En dråpe urinprøve legges på en glassplate. Så tilsettes A drop of urine sample is placed on a glass plate. Then added
en dråpe antihumant choriongonadotropinserum (kanin) og . ; one drop of antihuman chorionic gonadotropin serum (rabbit) and . ;
en forsiktig blanding utføres i 30 sekuner. Til den resul- a gentle mixing is carried out for 30 seconds. To the resul-
terende blanding settes en dråpe HCG-latexreagens frem- mixture, a drop of HCG latex reagent is added
stilt ifølge eksempel 1 i norsk patentansøkning 241/72.og den resulterende urin, antiserum, antigenblandingen blandes grundig, spres på platen og agglutineringen observeres. Hvis det ikke er noen agglutinering innen to minutter er forsøket positivt (graviditet). Hvis det er agglutinering innen to minutter er forsøket negativt. posed according to example 1 in Norwegian patent application 241/72. and the resulting urine, antiserum, antigen mixture are thoroughly mixed, spread on the plate and the agglutination is observed. If there is no agglutination within two minutes, the test is positive (pregnancy). If there is agglutination within two minutes, the test is negative.
EKSEMPEL 4 EXAMPLE 4
1 ml urinprøve settes til 2 ml antihumant choriongonadot- 1 ml of urine sample is added to 2 ml of antihuman chorionic gonadotropin
ropinserum (kanin) i et lite prøverør som inneholder HCG- ropin serum (rabbit) in a small test tube containing HCG-
latex som fremstilt ifølge eksempel I i norsk patentsøknad 241/72. Den resulterende reaksjonsblandingen blandes ved å latex as produced according to example I in Norwegian patent application 241/72. The resulting reaction mixture is mixed by
snu prøverøret 2 eller 3 ganger. Prøverøret plasseres så i et 37°C vannbad. Flokkuleringen i prøverøret observeres etter 90 minutter, hvis ingen flokkulering opptrer er forsøket positivt (graviditet), hvis flokkulering opptrer er forsøket negativt. invert the test tube 2 or 3 times. The test tube is then placed in a 37°C water bath. The flocculation in the test tube is observed after 90 minutes, if no flocculation occurs the test is positive (pregnancy), if flocculation occurs the test is negative.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11173771A | 1971-02-01 | 1971-02-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO138675B true NO138675B (en) | 1978-07-10 |
| NO138675C NO138675C (en) | 1978-10-18 |
Family
ID=22340179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO241/72A NO138674C (en) | 1971-02-01 | 1972-01-31 | IMMUNOLOGICAL-DIAGNOSTIC REAGENT. |
| NO1749/72A NO138675C (en) | 1971-02-01 | 1972-05-16 | DIAGNOSTIC PROCEDURE FOR DETECTION OF HUMAN CHORIONIC GONADOTROPINE, HUMAN ALBUMIN OR A RHEUMATOID FACTOR |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO241/72A NO138674C (en) | 1971-02-01 | 1972-01-31 | IMMUNOLOGICAL-DIAGNOSTIC REAGENT. |
Country Status (16)
| Country | Link |
|---|---|
| JP (3) | JPS5312966B1 (en) |
| AR (1) | AR195542A1 (en) |
| BE (1) | BE778697A (en) |
| DK (1) | DK132971C (en) |
| ES (1) | ES399338A1 (en) |
| FI (1) | FI55265C (en) |
| HU (1) | HU166709B (en) |
| IE (1) | IE36043B1 (en) |
| IL (1) | IL38563A (en) |
| IT (1) | IT959544B (en) |
| NO (2) | NO138674C (en) |
| PH (1) | PH10991A (en) |
| SE (1) | SE398674B (en) |
| TR (1) | TR17645A (en) |
| YU (1) | YU36228B (en) |
| ZA (1) | ZA72151B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01272965A (en) * | 1988-04-25 | 1989-10-31 | Nitto Denko Corp | Immobilized ph indicator |
| US7888844B2 (en) * | 2009-06-30 | 2011-02-15 | Avago Technologies Wireless Ip (Singapore) Pte. Ltd. | Temperature control of micromachined transducers |
| CN108473753B (en) | 2015-12-25 | 2020-07-24 | 东洋纺株式会社 | Polyester resin composition, light reflector element and light reflector containing same, and method for producing polyester resin composition |
| WO2018143100A1 (en) | 2017-02-02 | 2018-08-09 | 東洋紡株式会社 | Polyester resin composition, and light reflector component and light reflector including same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3088875A (en) * | 1959-10-27 | 1963-05-07 | Hyland Lab | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron |
| US3236732A (en) * | 1962-01-22 | 1966-02-22 | Edward R Arquilla | Pregnancy test method and immunological indicator therefor |
| SE343949B (en) * | 1966-06-02 | 1972-03-20 | Pharmacia Ab | |
| US3882225A (en) * | 1968-12-09 | 1975-05-06 | Miles Lab | Direct agglutination immunological reagent |
-
1972
- 1972-01-10 ZA ZA720151A patent/ZA72151B/en unknown
- 1972-01-14 IL IL38563A patent/IL38563A/en unknown
- 1972-01-25 IT IT19803/72A patent/IT959544B/en active
- 1972-01-26 TR TR17645A patent/TR17645A/en unknown
- 1972-01-27 PH PH13237A patent/PH10991A/en unknown
- 1972-01-28 IE IE119/72A patent/IE36043B1/en unknown
- 1972-01-31 BE BE778697A patent/BE778697A/en not_active IP Right Cessation
- 1972-01-31 JP JP1063572A patent/JPS5312966B1/ja active Pending
- 1972-01-31 SE SE7402780A patent/SE398674B/en unknown
- 1972-01-31 ES ES399338A patent/ES399338A1/en not_active Expired
- 1972-01-31 HU HUHO1452A patent/HU166709B/hu unknown
- 1972-01-31 FI FI239/72A patent/FI55265C/en active
- 1972-01-31 YU YU213/72A patent/YU36228B/en unknown
- 1972-01-31 NO NO241/72A patent/NO138674C/en unknown
- 1972-02-01 AR AR240326A patent/AR195542A1/en active
- 1972-02-01 DK DK43572*#A patent/DK132971C/en not_active IP Right Cessation
- 1972-05-16 NO NO1749/72A patent/NO138675C/en unknown
-
1977
- 1977-10-12 JP JP12157277A patent/JPS5394032A/en active Pending
-
1984
- 1984-03-19 JP JP59051309A patent/JPS59192960A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DK132971B (en) | 1976-03-01 |
| IL38563A (en) | 1975-06-25 |
| YU36228B (en) | 1982-02-25 |
| PH10991A (en) | 1977-10-20 |
| NO138674B (en) | 1978-07-10 |
| IT959544B (en) | 1973-11-10 |
| IL38563A0 (en) | 1972-03-28 |
| JPS5394032A (en) | 1978-08-17 |
| IE36043B1 (en) | 1976-08-04 |
| ZA72151B (en) | 1972-09-27 |
| ES399338A1 (en) | 1974-12-01 |
| FI55265B (en) | 1979-02-28 |
| JPS59192960A (en) | 1984-11-01 |
| TR17645A (en) | 1975-07-23 |
| FI55265C (en) | 1979-06-11 |
| JPS5312966B1 (en) | 1978-05-06 |
| SE398674B (en) | 1978-01-09 |
| HU166709B (en) | 1975-05-28 |
| YU21372A (en) | 1981-06-30 |
| JPS6119936B2 (en) | 1986-05-20 |
| DK132971C (en) | 1976-08-02 |
| AR195542A1 (en) | 1973-10-23 |
| BE778697A (en) | 1972-07-31 |
| NO138674C (en) | 1978-10-18 |
| IE36043L (en) | 1972-08-01 |
| NO138675C (en) | 1978-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3088875A (en) | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron | |
| US4062935A (en) | Immunoassay involving the binding of RF to the antigen-antibody complex | |
| EP0074520B1 (en) | Method and kit for pregnancy detection | |
| EP0110993A1 (en) | Particulate ligand assay-methods and products | |
| CN107942069A (en) | A kind of NGAL latex immunoturbidimetries detection kit and preparation method thereof | |
| US4711841A (en) | Method for determining one or more antigens in a sample | |
| US4138213A (en) | Agglutination immunoassay of immune complex with RF or Clq | |
| US4210622A (en) | Kit for assay of immune complexes | |
| CN108603880A (en) | The detection method of tested substance and the detection kit of tested substance | |
| US4141965A (en) | Assay of immune complexes | |
| US3562384A (en) | Immunological indicator and test system | |
| JP2824794B2 (en) | A method to search for and identify erythrocyte antibodies by solid-phase method | |
| JPS6217188B2 (en) | ||
| EP0402993B1 (en) | Diagnostic test kit and method for determination of chlamydial antigen using a membrane having surface hydroxy groups | |
| NO138675B (en) | DIAGNOSTIC PROCEDURE FOR DETECTION OF HUMAN CHORIONIC GONADOTROPINE, HUMAN ALBUMIN OR A RHEUMATOID FACTOR | |
| JP2553852B2 (en) | Immunological assay for biological substances in samples | |
| EP0280557B1 (en) | Test kit, extraction device and method for the determination of streptococcus a antigen | |
| EP0134868A1 (en) | Unicellular organisms activated by glutaraldehyde as solid carriers for sensitizing agents and uses of sensitized unicellular organisms | |
| US4937201A (en) | Latex reagent for detection of the toxin of clostridium difficile | |
| US4403040A (en) | Diagnostic test for the detection of a specific tumor antigen with CoA-SPC | |
| JP3618797B2 (en) | Immunoassay | |
| NO138394B (en) | PROCEDURE FOR AA DETERMINING THE PRESENCE OF AUSTRALIA ANTIGEN IN A BLOOD TEST | |
| JPH08327629A (en) | Pretreatment of specimen | |
| US3733398A (en) | Determining and reversing anticomplementary activity in complement fixation test for australia antigen | |
| JPH0684972B2 (en) | Latex agglutination reaction reagent |